Zynerba Pharma is an innovative and forward-thinking biopharmaceutical company that focuses on developing transdermal cannabinoid treatments for neuropsychiatric disorders. With a mission to improve the lives of patients battling rare conditions, Zynerba Pharma takes a different approach to delivering these treatments. By prioritizing the unmet medical needs of patients and their families, the company is dedicated to advancing science and improving connections in the field of medicine.

Zynerba Pharma's pipeline consists of cutting-edge therapies, including their flagship product Zygel TM, which is currently undergoing clinical trials. This product aims to address the specific needs of patients with neuropsychiatric conditions, offering new hope and potential treatment options. The company thrives on a team of experts, including their management, board of directors, and scientific advisory boards.

Zynerba Pharma is committed to pushing the boundaries of pharmaceutical manufacturing and remains focused on rare disorders and the potential of cannabinoids in addressing these conditions. For the latest news, updates, and information on Zynerba Pharma, including their research and advancements, visit their website and follow them on LinkedIn and Twitter